| DC65769 |
1-Stearoyl-2-myristoyl-sn-glycero-3-PC
Featured
|
1-Stearoyl-2-myristoyl-sn-glycero-3-PC (1S-2M-PC) belongs to the class of asymmetric phospholipids. 1-Stearoyl-2-myristoyl-sn-glycero-3-PC is abundant in biological membranes. |
|
| DC65770 |
DMPE-mPEG2000(Na salt)
Featured
|
|
|
| DC65772 |
rac-1,2-Distearoyl-3-chloropropanediol
Featured
|
rac-1,2-Distearoyl-3-chloropropanediol is a biochemical reagent that can be used as a biological material or organic compound for life science related research. |
|
| DC65773 |
1,2-Distearoyl-sn-glycerol
Featured
|
1,2-Distearoyl-sn-glycerol (DSG; 1,2-Dioctadecanoyl-sn-glycerol) acts as an internal standard for Separation and identification of molecular species of 1,2-diacyl-sn-glycerol (DAG). |
|
| DC65774 |
1,2-Dipalmitoyl-rac-glycerol
Featured
|
1,2-Dipalmitoyl-rac-glycerol is a diacylglycerol containing palmitic acid at the sn-1 and sn-2 positions. It is found in a variety of vegetable oils, including palm, soybean, canola, and corn. 1 \n 1,2-Dipalmitoyl-rac-glycerol MaxSpec Standard is a quantitative grade standard of 1,2-dipalmitoyl-rac-glycerol prepared for mass spectrometry and related applications requiring quantitative reproducibility . The solution has been prepared gravimetrically and contained in argon-sealed deactivated glass ampoules. Concentrations were verified by comparison to independently prepared calibration standards. This 1,2-dipalmitoyl-rac-glycerol MaxSpec Standard is guaranteed to meet specifications for identity, purity, stability, and concentration and is supplied with a batch-specific Certificate of Analysis. Ongoing stability testing is performed to ensure concentrations remain accurate throughout the shelf life of the product. Note: Add more solution to the vial than listed. Therefore, accurate volume measurements are necessary to prepare calibration standards. Follow recommended storage and handling conditions to maintain product quality. |
|
| DC65775 |
1,3-Dipalmitoyl-2-oleoyl Glycerol
Featured
|
|
|
| DC65776 |
1,2-Dipalmitoyl-sn-phosphoglycerol(ammonium sait)
Featured
|
|
|
| DC65782 |
1-Oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine
Featured
|
1-Oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine is the main degradation product of deltamethrin metabolized by the prokaryotic protein (CYP6A14 and CYP6N6) complexes in vitro. |
|
| DC65783 |
JDN18957
Featured
|
Also known as 1-Stearoyl-2-Oleoyl-sn-glycero-3-PE. It is is a phospholipid that contains stearic acid and oleic acid |
|
| DC65784 |
SOPA-NA(18:0-18:1 PA)
Featured
|
|
|
| DC65786 |
mPEG2000-DSPE
Featured
|
mPEG2000-DSPE is used in COVID 19 mRNA vaccines. It is a PEGylated derivative of 1,2-distearoyl-sn-glycero-3-PE . Formulations containing DSPE-MPEG(2000) have been used to prepare liposomes with long circulation time for the delivery of anticancer and antimalarial agents.. mPEG2000-DSPE has also been widely used as hydrophilic surface modifying agent for a variety types of hydrophobic nanoparticles, including recently reported lipid nanoparticle mRNA vaccines. |
|
| DC65789 |
HUN86681
Featured
|
HUN86681, also known as 1-Hexadecyl-2-acetylphosphatidylcholine, is a lipid Platelet activating factor (PAF). PAF is an ether phospholipid known to exhibit potential biological activities in a variety of cellular phenomena such as platelet aggregation, chemotaxis, hypotension, bronchoconstriction, vascular permeability regulation, inflammation, glycogenesis and in regular cellular breakdown of phosphatidylinositol. |
|
| DC65790 |
1,2-Dipalmitoyl-sn-glycerol
Featured
|
1,2-Dipalmitoyl-sn-glycerol is an endogenous metabolite. |
|
| DC65791 |
DPPG sodium
Featured
|
|
|
| DC65792 |
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine
Featured
|
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can be chosen as a model used to investigate the volatile compounds from oxidised phosphatidylcholine molecular species. This method is applied to a real food sample, i.e. soy lecithin. |
|
| DC65794 |
O-LySoPC
Featured
|
|
|
| DC65795 |
2-Bromoisobutyric acid((s)-1，2-dimyristoyl-SN-giycerol)ester
Featured
|
|
|
| DC65798 |
DBr-1
Featured
|
DCAF1-BRD9 PROTAC DBr-1 potently degrades BRD9 with a DC50 of 90 nM but only weakly affected BRD7 protein levels. DBr-1 provides an alternative strategy to tackle intrinsic resistance to VHL-degrader. |
|
| DC65799 |
Compound 38 (NNMT inhibitor)
Featured
|
Compound 38 (NNMT inhibitor) is a potent uncompetitive inhibitors of nicotinamide n-methyltransferase (NNMT). Compound 38 inhibits NNMT in both in vitro biochemical and cell-based assays with IC50 = 42 nM and 38 nM, respectively. Compound 38 shows favorable PK/PD and safety profiles as well as excellent oral bioavailability and pharmaceutical properties. |
|
| DC65800 |
ARV-393
Featured
|
ARV-393 is an orally active PROTAC that utilizes the ubiquitin-proteasome system to target the degradation of BCL6. ARV-393 consists of ligand conjugates targeting BCL6 and the E3 ligase cereblon, respectively. ARV-393 has DC50 and GI50 values of <1 nM in multiple cell lines of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ARV-393 also demonstrated considerable tumor suppressor activity in tumor xenograft models. ARV-393 is being studied to inhibit non-Hodgkin lymphoma. |
.gif)
|
| DC65801 |
ARV-102
Featured
|
a LRRK2 degrader for the treatment of PD and PSP |
|
| DC65803 |
KT-294
Featured
|
a TYK2 degrader for multiple immune-mediated diseases. |
|
| DC65804 |
HP518
Featured
|
an AR degrader for the treatment of mCRPC. |
|
| DC65805 |
BMS-986365 (CC-94676)
Featured
|
BMS-986365 (CC-94676) is a highly potent and selective AR degrader that induces rapid and deep degradation of both wildtype and mutant forms of the receptor residing in either the cytoplasmic or nuclear compartments of the cell. BMS-986365 (CC-94676) is about 100-fold more potent than enzalutamide (ENZ) at inhibiting androgen-stimulated transcription of AR target genes, and 10 to 120-fold more potent than ENZ at inhibiting AR-dependent proliferation of multiple prostate cancer cell lines in vitro. |
|
| DC65806 |
AC682
Featured
|
an ER degrader for the treatment of BC. |
|
| DC65807 |
BGB-16673
Featured
|
a BTK degrader for the treatment of B-cell malignancies. |
|
| DC65808 |
HSK-29116
Featured
|
a BTK degrader for the treatment of B-cell malignancies. |
|
| DC65809 |
CG001419
Featured
|
a mutant and wild-type NTRK degrader for the treatment of solid tumors. |
|
| DC65810 |
KT-333
Featured
|
KT-333 is a molecular glues that degrades STAT3 protein. KT-333 mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL). |
|
| DC65811 |
KT-253
Featured
|
a MDM2 degrader for the treatment of r/r high grade myeloid malignancies and solid tumors. |
|
